Application Number INFORMATION DISCL Confirmation Number STATEMENT BY APA Filing Date December 14, 2004 Form PTO-1449 (Modified) GEDULIN, Bronislava First Named Inventor (Use several sheets if necessary) 1646 Group Art Unit Examiner Name Not yet assigned Ruixiana of Sheet Attorney Docket No. 54061.8101.US01

 	-				U.S	PATENT DOCUMENTS				
Examiner Initials*	Cite No.			nd Code		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines Where Relevant Passages Relevant Figures Appea	or	
RLi	AA	5,604,			Bala	subramaniam	Oct. 24, 1994			
000 1000		+		+ +		ي المرابع المرابع المرابع المرابع المعاملة المرابع المرابع المعاملة المرابع المرابع المرابع المرابع		an an arrangemental meneral and arrangement	errica inter	131849
	1			11		" - •				
	<u></u>	·		F(OREI	GN PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Fore	eign Patent or A	Application Kind (Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
		J								
						ION PATENT LITERATURE D				
Examiner Initials*	Cite No.	(bool	include name o k, magazine, jo	f the authorimal, seri	or (in C al, syn	APITAL LETTERS), title of the article posium, catalog, etc.), date, page(s), and/or country where published.	(when appropriate) volume issue numb	, title of the item per(s), publisher, city	т	
RLi	AB	and Y2	agonists of	devoide	ed of	derivatives as selective n factivity for the Y3 receptor 6, Issue 1-2, pp. 320-324	or subtype. E			
RLi			EL-SALHY et al., Peptide YY in gastrointestinal disorders. Peptides, Feb. 2002,							PF #TEBERS
	+									
									_	

EXAMINER		DATE CONSIDERED					
	Rudxiang Lj	7/8/206					
*EXAMINER:	Initial if reference considered, whether or not criteria is in conform	mance with MPEP 609. Draw line through citation if not in conformance and not					
	considered. Include copy of this form with next communication to application(s).						

	INFORMATION STATEMENT E Form PTO-14 Use several she		FEB 2 8 205 CAB JULY PRACES
\neg	1	of	1

Sheet

	COMPLETE IF KNOWN
Application Number	10/518,128
Confirmation Number	
Filing Date	December 14, 2004
First Named Inventor	Gedulin, Bronislava
Group Art Unit	1646
Examiner Name	Notyetassigned Ruixiana Li
Attorney Docket No.	54061.8101.US01

					U.S	. PATENT DOCUMENTS			
Examiner Initials*	r Cite	te		ication ind Code if known)		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages Relevant Figures Appear	or
	+	+							
was in 1	. *** ***-			F	OREI	IGN PATENT DOCUMENTS	min no constant	のなったのかときというというないなったのではないというないないできます。	escorio de
Examiner Initials*	r Cite	te	oreign Patent or A	Kind (n Code nown)	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ
Hilder	+	0.1100	NONDE	10.10.	J.,	Of Orod Dodding	Document	Figures Appear	$\dagger \dagger$
	+	1					 		H
		1							\Box
	1			-					\Box
			OTHER	PRIOR /	₩T-I	NON PATENT LITERATURE D	OCUMENTS	<u>:</u>	+
Examiner Initials*	Cite No.	(bo	Include name o ok, magazine, je	of the authoroumal, ser	or (in C ial, syr	CAPITAL LETTERS), title of the article mposium, catalog, etc.), date, page(s), and/or country where published.	(when appropriate) , volume issue numb	, title of the item per(s), publisher, city	Ţ
RLi	AA					lling, R. and Grimelius, L. (1997 tern Med 242, 413-419.	') Colonic endo	crine cells in	
	АВ					J.A. and Go, V.L. (1988) Peptiinflammatory bowel disease. De			\prod
Track to Europe to the	AC			Y abnom	malitie	laruma, K., Ohgoshi, H., Yoshih es in patients with ulcerative col	olitis. Jpn J Med	27, 49-55.	An 124 14
1	AD	Lanspa,	Terment, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., anspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal ouch function and release of peptide YY. <i>Dis Colon Rectum</i> 41, 868-874.						
RL;	Teshima, H., Tari, A., Sumii, K., Yoshihara, M., Ohgoshi, H., Fukuhara, I., Tokumo, K., Haruma, K., Kajiyama, G., Miyachi, Y. and et, a.l. (1987) [Plasma peptide YY-like immunoreactivity in ulcerative colitis, colorectal cancer, and colectomy]. Nippon Shokakibyo Gakkai Zasshi 84, 2681-2687.				activity in ulcerative				
	<u>'</u>	<u></u>							

EXAMINER	_	DATE CONSIDERED
	Ruixiang Li	7/8/206
*EXAMINER:	Initial if reference considered, whether or not criteria is in confort considered. Include copy of this form with next communication t	nance with MPEP 609. Draw line through citation if not in conformance and not o application(s).

PTO/SB/08A (07-05)

Under the Peperwork Reduction Act of 1985, no persons are required t	U.S. Petent and Treder	mark Office; U.S. DEPARTMENT OF COMA	MERCE
Substitute for form 1449/PTO		mplete if Known	
Substitute of the teach to	Application Number	10/518,128	
INFORMATION DISCLOSURE	Filing Date	June 13, 2003	
	First Named Inventor	Bronislava Gedulin	
STATEMENT BY APPLICANT	Art Unit	1646	
(Uso as many sheets as necassary)	Examiner Name	LI, RUIXIANG	
	Attorney Docket Mumber	18782-1111-E	

Examiner Indiais*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentage or Applicant of Cited Document	Pages, Columns, Unas, Where Relevant Passages or Relevant Figures Appear	
	NAO.	Number-Kind Code ^{2 (/ hum)}		Applicant of October Document		
RLI		^{US-} 2003/0224983 A1	12-4-2003	Nielsen, Hoiriis Jens		
RLi		^{US-} 6,569,832 B1	05-27-2003	Knudsen et al.		
		US-				
		US-	T			
		US-				
		us-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				
		US-				
		US-				
		US-				
		US-			1	
		Us-	·		†	
	 	UŞ-	- 	-	 	
		us-		 		

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	_a
		Country Code* "Number* "Kind Code* (# known)	MM-DD-YYYY		Or Relevant Figures Appaar	
				·		
						 -
						┡
						┢
						H

Examiner	0	Dete	_1s1_ /
Signature	kuixiang hi	Considered	7/8/2006
	1,000,11		<u> </u>

"EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 509. Draw line through cliation if not in conformance and not considered, include copy of this form with need communication to applicant. 'Applicant's unique cliation designation number (options). "See Kinds Codes of USPTO Petent Documents at www.uspin.com or MPEP 901.04. "Enter Office that issued the document, by the two-tetter code (WIPO Standard ST.3). "For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Afford of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and automitting the completed application form to the USPTO. Time will very depending upon the bridylduid case. Any comments on the owner of time you require to complete his form another suggestions for reducing the burden, should be sent to the Clief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

PTO/SB/08B (07-06)
Approved for use through 07/31/2008. OMB 0551-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB contains.

Subetth	to for form 1448/PTO				Complete if Known	
, G00300				Application Number	10/518,128	·
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislave Gedulin	
	Oten en mens els			Art Unit	1646	
	(Usu es many sheets as necessary)			Examiner Name	LI, RUIXIANG	
Sheet	2	of	2	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RLi		Towfigh et al., Surgical Forum Vol. 50: 25-27 (1999)	
	,		
	·		
	;		

Examiner	Q xxx A A i	Date	212/22/
Signature	Kuixiang hi	Considered	7/8/206

"EXAMPLES: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not

"EXAMPLER: Initial if reference considered, whether or not disting is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (aptional). 2 Applicant is to place a check mark here if English language Translation is statched.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gatheting, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Tradament Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

APR 0 3 2006 respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act

Substitute for form 1449/PTO

Sheet |1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known **Application Number** 10/518,128 Filing Date June 13, 2003 First Named Inventor Bronislava Gedulin Art Unit 1646 **Examiner Name** LI, RUIXIANG 0402-UTL-5 Attorney Docket Number

			U. S. PATEN	DOCUMENTS	
Exeminer Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ² (F known)			Figures Appear
RLi		^{US-} 4,683,195	7-28-1987	Mullis et al.	
1		^{US-} 4,683,202	7-28-1987	Mullis	
		US- 4,839,343	6-13-1989	Waeber et al.	·
		^{US-} 4,891,357	01-02-1990	Kala	
		^{US-} 4,892,538	01-09-1990	Aebisher et al.	
		^{US-} 5,459,039	10-17-1995	Modrich et al.	
		^{US-} 5,498,531	03-12-1996	Jarrell	1
		US- 5,574,010	11-12-1996	McFadden	
		^{US-} 5,696,093	12-09-1997	Tseng	
		^{US-} 5,824,784	10-20-1998	Kinstler et al.	
		^{US-} 5,824,778	10-20-1998	Ishikawa et al.	
		^{US-} 5,912,227	06-15-1999	Croom, Jr. et al.	
		^{US-} 5,939,462	08-17-1999	Connell et al.	
		^{US-} 5,968,819	10-19-1999	Gerald et al.	
		us- 5,980,945	11-9-1999	Ruiz	
		^{US-} 6,013,622	01-11-2000	Bruno et al.	. \
		^{US-} 6,315,203	11-13-2001	lkeda et al.	
V		^{US-} 6,355,478	03-12-2002	Baez et al.	
RLi	<u> </u>	^{US-} 6,391,343	05-21-2002	Yen	\

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ³ (# known)	MM-DD-YYYY	.,	Or Relevant Figures Appear	T⁵
RY		EP 0 992 239 B1	03-12-2003	Banyu Pharma Co Ltd		
1		WO 83/04053	11-24-1983	Applied Molecular Genetic		
		WO 89/01967	03-09-1989	Brown University Research		Г
		WO 90/02580	03-22-1990	Brown University Research		
¥		WO 90/15637	12-27-1990	Brown University Research		
RL;		WO 91/10425	07-25-1991	Brown University Research		

Examiner	0 7 0	Date	
Signature	Krudians I.	Considered	1 7/8/206
L -	/ // /		, , ,

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ś

Substitute for form	1449/PTO	Col	mplete if Known	
4000000000000000000000000000000000000		Application Number	10/518,128	
INFORM	ATION DISCLOSURE	Filing Date	June 13, 2003	
		First Named Inventor	Bronislava Gedulin	
	ENT BY APPLICANT	Art Unit	1646	
(Use	as many sheets as necessary)	Examiner Name	LI, RUIXIANG	
12	. 24	Attorney Docket Number	0402 LITL 5	

			U. S. PATEN	F DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
RLI		US- 6,420,532	07-16-2002	Gerald et al.	
1		^{US-} 6,558,708 B1	05-06-2003	Lin	
		^{US-} 6,734,166	05-11-2004	Croom, Jr. et al.	
-		^{US-} 2002/0094346-A1	07-18-2002	Lin	
RL;		^{US-} 2004/0228846	11-18-2004	Pang et al.	
		US-	•		
		US-		1	
		US-			
		US-	,		
		US-			
		US-	 	 	
		US-	+		

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ "Kind Code ³ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
RLi		WO 91/10470	07-25-1991	Brown University Research		
		WO 94/16101	07-21-1994	Hubert Koster		
		WO 99/07404	02-18-1999	Amylin Pharmaceuticals, I		
		WO 99/15516	04-01-1999	Banyu Pharma Co Ltd		
V		WO 99/25727	05-27-1999	Amylin Pharmaceuticals, I		
RLi		WO 99/25728	05-27-1999	Amylin Pharmaceuticals, I		↸

Examiner Rustiang Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officar, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 6651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	Cor	mplete if Known
	Application Number	10/518,128
INFORMATION DISCLOSURE	Filing Date	June 13, 2003
	First Named Inventor	Bronislava Gedulin
STATEMENT BY APPLICANT	Art Unit	1646
(Use as many sheets as necessary)	Examiner Name	LI, RUIXIANG
Sheet 3 of 31	Attorney Docket Number	0402-UTL-5

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
		Number-Kind Code ^{2 (# known)}	<u> </u>		Figures Appear
		US-			
		US-			,
		US-			
		US-			
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
w		US-			
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-	1		
		US-	 		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	L	Country Code ³ "Number ⁴ "Kind Code ⁵ (il known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
RLi		WO 00/47219	08-17-2000	Ontogeny, Inc.		T
1		WO 00/68197	11-16-2000	Ortho McNeil Pharm		
		WO 01/62737	08-30-2001	Ortho McNeil Pharm		Г
		WO 01/76631	10-18-2001	Cedars Sinai Medical		
V		WO 03/026591 A2	04-03-2003	Imperial College		abla
RLi		WO 03/057235	05-17-2003	Imperial College		

Examiner Signature	Ruining La	Date Considered	7/8/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Application Number 10/518,128

Filing Date June 13, 2003

First Named Investor Conductor Control

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number 10/518,128
Filing Date June 13, 2003
First Named Inventor Bronislava Gedulin
Art Unit 1646
Examiner Name LI, RUIXIANG
Attorney Docket Number 0402-UTL-5

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (f known)}			I iguies repeat
		US-			
		US-			T
		US-			
·····	<u> </u>	US-			
		US-	† · · · · †		
	 	US-			
		US-	 		
		US-			
		US-			
		US-			
	 	US-			
		US-	† † † † † † † † † † † † † † † † † † †		
	<u> </u>	US-		······································	
		US-			
	 	US-	 		

		FOREI	GN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ³ (if Innown)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
RLi		WO 03/105763	12-24-2003	Amylin Pharmaceuticals, I		
	<u> </u>					
	ļ					igwdap
<u> </u>	<u> </u>					▙
	<u> </u>	L			<u> </u>	

Examiner	0	Date /. /	
Signature	Kushang J.	Considered) / ៛ / シャ	6

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Approved for use through 07/31/2006. OMB 0651-003
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995,	no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

	rte for form 1449/PTC				Complete if Known
Subsulu	ne iorioini 1445/FTC	,		Application Number	10/518,128
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many s	haata aa s		Art Unit	1646
	(Use as many s	neets as n	recessary)	Examiner Name	LI, RUIXIANG
Sheet	5	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Adrian, T.E., et al., Gastroenterology 89, 1070-1077 (1985)	
		Adrian, T.E., et al., Digestion 21, 214-218 (1981)	
		Ahren, B. et al., Eur J Endocrinol 134, 362-365 (1996)	
		Allen, J.M., et al., Digestion 30, 255-262 (1984)	
		Ando, R., et al., Eur J Pharmacol 427, 53-59 (2001)	
		Andres, C.J., et al., Bioorg Med Chem Lett 13, 2883-2885 (2003)	
		Aponte, G.W., et al., FASEB J 3, 1949-55 (1989)	
		Aponte, G.W. Peptides 23, 367-376 (2002)	
\downarrow		Asakawa, A., et al., Peptides 20, 1445-1448 (1999)	
RLi	.	Bader, R., et al., Biochemistry 41, 8031-8042 (2002)	

	<u> </u>		
Examiner	2	Date	-10.1-
Signature	Kurling L	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a unit OMB.

	Substitute for form 1449/PTO			Complete if Known		
000300	NO IOI IOIII 14407 TO			Application Number	10/518,128	
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	(Use as many she	ote ce s	acassan/l	Art Unit	1646	
	(038 as many site		ecosaly)	Examiner Name	LI, RUIXIANG	
Sheet	6	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
RLi		Balasubramaniam, A., et al., Peptides 14, 1011-1016 (1993)		
	-	Balasubramaniam, A., et al., Int J Pept Protein Res 29, 78-83 (1987)		-
	·	Balasubramaniam, A., et al., Pept Res 1, 32-35 (1988)		
		Balasubramaniam, A., et al., Peptides 23, 1485-1490 (2002)		
		Balasubramaniam, A., et al., J Med Chem 43, 3420-3427 (2000)		-
		Balasubramaniam, A.A. Peptides 18, 445-457 (1997)		_
		Barany, F. Proc Natl Acad Sci U S A 88, 189-193 (1991)		
		Bartlett PA, et al., Bioorg Chem.14:356-377 (1986)		_
		Batterham, R.L., et al., N Engl J Med 349, 941-948 (2003)		
RLi		Batterham, R.L., et al., Nature 418, 650-654 (2002)	1	-

Examiner	3 7 7	Date / /	
Signature	Rushang L.	Considered $7/8/2 \sim 6$	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	uuion A	A UL 1985, NO PERSONS BI	required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Guusaa	10 10 10 11 14-01 10			Application Number	10/518,128	
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	(Use as many sheets as necessary)			Art Unit	1646	
	(USE as many and	013 63 11		Examiner Name	LI, RUIXIANG	
Sheet	7	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	2
		Beck, A., et al., FEBS Lett 244, 119-122 (1989)		
		Beck-Sickinger, A.G., et al., J Recept Res 13, 215-228 (1993)		_
		Beltowski, J. et al., Pol J Pharmacol 56, 5-27 (2004)		-
i		Berge, S.M., et al., J Pharm Sci 66, 1-19 (1977)		=
		Berglund, M.M., et al., Exp Biol Med (Maywood) 228, 217-244 (2003)		-
		Bertrand, G., et al., Pancreas 7, 595-600 (1992)		
		Birdsall, N.J.M. et al., Trends Pharmacol Sci 4, 459-463 (1983)		=
		Bischoff, A. et al., Trends Pharmacol Sci 20, 104-106 (1999)		
		Bonaz, B., et al., Neurosci Lett 163, 77-80 (1993)		=
RL;		Bottcher, G., et al., Pancreas 4, 282-288 (1989)		=

Examiner Signature	Ruxing L	Date Considered	7/8/206

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	te for form 1449/PTO	oudon'r	ot or 1000, no poroons at	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
0.000	101010111111111111			Application Number	10/518,128	
INF	ORMATION	N DIS	CLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Bronislava Gedulin	
	(Use as many sh	aate ae i	nocoecany)	Art Unit	1646	
	(USO as many sin	0013 83 7	accessury)	Examiner Name	LI, RUIXIANG	
Sheet	8	of	31	Attorney Docket Number	0402-UTL-5	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	, -				
Initials* Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
RLi		Boublik, J.H., et al., J Med Chem 32, 597-601 (1989)					
		Bourguet E, et al., Bioorg Med Chem Lett.13:1561-1564 (2003)					
		Bousquet-Melou, A., et al., J Lipid Res 36, 451-461 (1995)					
		Brown, K.K., et al., Diabetes 48, 1415-1424 (1999)					
		Cabrele, C. et al., J Pept Sci 6, 97-122 (2000)					
		Cabrele, C., et al., J Biol Chem 275, 36043-36048 (2000)					
		Cabrele, C., et al., Biochemistry 41, 8043-8049 (2002)					
		Cabrele, C., et al., Peptides 22, 365-378 (2001)					
		Camilleri, M., et al., Gut 22, 14-18 (1981)					
RLi		Campfield, L.A., et al., Science 269, 546-549 (1995)					

Examiner	2.1:4	Date _/6	back
Signature	Kinsiling In	Considered 7/8	12546

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The second second

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	te for form 1449/PTO			Complete if Known			
3003010	10101101111114437770			Application Number	10/518,128		
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Bronislava Gedulin		
	(Use as many she			Art Unit	1646		
	(OSe as many site	HUS 43 I	iecessary)	Examiner Name	LI, RUIXIANG		
Sheet	9	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RLi		Chance WT, et al., Life Sci.58:1785-1794 (1996)			
		Chen, C.H. et al., Am J Physiol 269, R787-R792 (1995)			
		Chen, C.H., et al., Regul Pept 61, 95-98 (1996)			
		Chen, C.H., et al., Neurogastroenterol Motil 9, 109-116 (1997)			
		Chen, M.H., et al., Sensitive Gastroenterology 87, 1332-1338 (1984)	Ï		
		Chen, Z., et al., FEBS Lett 492, 119-122 (2001)			
		Clark, J.T., et al., Endocrinology 115, 427-429 (1984)			
		Clark, J.T., et al., Regul Pept 17, 31-39 (1987)			
		Conlon, J.M. Peptides 23, 269-278 (2002)			
RLi		Cook, D.L. et al., Nature 311, 271-273 (1984)		[

Examiner	2 .	Date/e	1 1
Signature	Kindling L.	Considered //6	120-16

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO			Complete if Known		
00000				Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Bronislava Gedulin	
	(Use as many si	haote se r	necessari)	Art Unit	1646	
	(030 03 111011) 21			Examiner Name	LI, RUIXIANG	
Sheet	10	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RLi		Corp, E.S., et al., Peptides 22, 493-499 (2001)	
		Corp, E.S., et al., Am J Physiol 259, R317-R323 (1990)	
		Coruzzi, G., et al., Arch Int Pharmacodyn Ther 302, 232-241 (1989)	
		Cotton, R.G. Mutat Res 285, 125-144 (1993)	
		Cotton, R.G., et al., Proc Natl Acad Sci U S A 85, 4397-4401 (1988)	
		Cox, H.M. et al., Br J Pharmacol 101, 247-252 (1990)	
		Cox, H.M., et al., J Physiol 398, 65-80 (1988)	
		Cox, H.M., et al., Regul Pept 75-76, 3-8 (1998)	
		Dea, D., et al., Gastroenterology 96, 695-703 (1989)	1
RLi	1	Deng, X., et al. Dig Dis Sci 46, 156-165 (2001)	1

					7
Examiner Signature	Runding	む	 Date Considered	7/8/206	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Aboxandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI

	ite for form 1449/PTO	uodion A	ct or 1000, no porosino ci	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Gubsuu	10 10 10 11 140 10			Application Number	10/518,128		
INF	ORMATION	N DIS	CLOSURE	Filing Date	June 13, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Bronislava Gedulin		
	(Use as many sh	oote se r	acassan)	Art Unit	1646		
	(USO ES MENY SI	10012 03 1	acasai y	Examiner Name	LI, RUIXIANG		
Sheet	11	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RLi		Dox, I.G., et al., Definition of 'islet'. In: Anonymous The HarperCollins Illustrated Medical Dictionary, 1st edn. pp. 227 New York: HarperCollins Publishers, Inc.] (1993)			
		Dumont, Y., et al., Eur J Pharmacol 238, 37-45 (1993)			
		Dumont Y, et al., Society for Neuroscience Abstracts. 1993;19:726. Abstract 299.8.			
		Eberlein, G.A., et al., Peptides 10, 797-803 (1989)			
		Ebert, R. Z Gastroenterol Verh 23, 165-170 (1988)			
		Eto, B., et al., Peptides 16, 1403-1409 (1995)			
		Fackelmann USA Today, Health and Science Gut hormone could curb urge to overeat. (Aug 7 2002)			
		Feinstein, R.D., et al., J Med Chem 35, 2836-2843 (1992)			
		Ferber, S., et al., Journal of Biological Chemistry 269, 11523-11529 (1994)	1		
RLi		Fournier, A., et al., Mol Pharmacol 45, 93-101 (1994)			

				_
Examiner Signature	Rushing L.	Date Considered	7/8/2006	i

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO				Complete If Known		
				Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	(Use as many s	haate se r	accessor)	Art Unit	1646	
	(use as many shous as nocessary)			Examiner Name	LI, RUIXIANG	
Sheet	12	of	31	Attorney Docket Number	0402-UTL-5	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	_
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RL;		Freshney, R.I. (Ed.) Culture of Animal Cells: A Manual of Basic Technique, pp. 4 New York: Alan R. Liss, Inc] (1983)	
-		Garlicki, J., et al., Am J Physiol 258, E40-E4 (1990)	
		Gedulin, B., et al., Gastroenterology 108, A604 (1995)	
		Gehlert, D.R. Proc Soc Exp Biol Med 218, 7-22 (1998)	
	·	Gibbs, R.A., et al., Nucleic Acids Res 17, 2437-2448 (1989)	
		Gobbi, M., et al., J Neurochem 72, 1663-1670 (1999)	
		Gold, G., et al., Diabetes 30, 77-82 (1981)	
		Gomez, G., et al., Am J Physiol 268, G71-G81 (1995)	
		Goodlad RA, et al., Digestion. 46 Suppl 2:177-181 1990	
RLi	1	Gordon, E.A., et al., Neurosci Lett 119, 187-190 (1990)	

			•
Examiner	Rundians J.	Date	7/8/2016
Signature	in the same of the	Considered	110 1256

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

0402-UTL-5

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/518,128 INFORMATION DISCLOSURE Filing Date June 13, 2003 STATEMENT BY APPLICANT **First Named Inventor** Bronislava Gedulin Art Unit 1646 (Use as many sheets as necessary) **Examiner Name** LI, RUIXIANG

Attorney Docket Number

13

31

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
RLi	Grandt, D., et al., Regul Pept 51, 151-159 (1994)		
		Grandt, D., et al., Biochem Biophys Res Commun 186, 1299-1306 (1992)	
		Greeley, G.H. Jr, et al., Proc Soc Exp Biol Med 189, 325-328 (1988)	
		Greeley, G.H. Jr, et al., Am J Physiol 254, E513-E517 (1988)	
		Grieco P, et al., Tetrahedron Lett.43:6297-6299 (2002)	
		Groth, C.G., et al., Transplant Proc 24, 972-973 (1992)	
		Grouzmann, E., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 519B (1993)	
		Grundemar, L., et al., Regul Pept 62, 131-136 (1996)	
		Gu X, et al., Tetrahedron Lett. 44:5863-5866 (2003)	
RLi		Guan, D., et al., Endocrinology 128, 911-916 (1991)	Ì

Examiner	2	A	Date	-101-
Signature	Kendân	8 th	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
Oddou				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she		economia de la conomia de la c	Art Unit	1646
	(USB as many six	7013 d3 /	iecessary)	Examiner Name	LI, RUIXIANG
Sheet	14	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS		ĺ
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	, T²	
RLi		Gue, M., et al., Br J Pharmacol 118, 237-242 (1996)	ripopiani ripopiani	an eta area eta eta eta eta eta eta eta eta eta e
}		Gustavsson, S., et al., Scand J Gastroenterol 12, 993-997 (1977)		
		Hagan, M.M. et al., Pharmacol Biochem Behav 45, 941-944 (1993)		
		Halaas, J.L., et al., Science 269, 543-546 (1995)		
		Halatchev, I.G., et al., Endocrinology 145, 2585-2590 (2004)		
		Hanessian S, et al., Tetrahedron 53:12789-12854 (1997)		
		Harding, R.K. et al., Peptides 10, 21-24 (1989)		
		Haynes, J.M., et al., Br J Pharmacol 122, 1530-1536 (1997)		
		Henry, M., et al., Obes Res 13, 36-47 (2005)		Barol Carollella of Mass still
RLi		Hoentjen, F., et al., Scand J Gastroenterol 35, 166-171 (2000)		!

Examiner	0 5 . 1	Date	1.1.
Signature	Rushing L	Considered	7/8/2-6
ACVANIANCE. L.	201-114	(II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995.	no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	Substitute for form 1449/PTO		Complete if Known		
Substitute for the reasons				Application Number	10/518,128
INF	ORMATION	N DIS	CLOSURE	Filing Date	June 13, 2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin
				Art Unit	1646
(Use as many sheets as necessary)			iecessary)	Examiner Name	LI, RUIXIANG
Sheet	15	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	ı	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RL;		Holliday, N.D. et al., Br J Pharmacol 119, 321-329 (1996)		
		Hsu, I.C., et al., Carcinogenesis 15, 1657-1662 (1994)	i overziesta	pak, mokarisme njektapini politici
		Hu, Y., et al., J Biol Chem 271, 26315-26319 (1996)		
		Hughes, S.D., et al., Proceedings of the National Academy of Sciences of the United States of America 89, 688-692 (1992)		
		Inui, A. Trends Pharmacol Sci 20, 43-46 (1999)		
		lyengar, S., et al., J Pharmacol Exp Ther 289, 1031-1040 (1999)		
		Jackerott, M. et al., Endocrinology 138, 5013-5018 (1997)		
		Jackerott, M., et al., J Histochem Cytochem 44, 809-817 (1996)		
		Johnson, J.H., et al., Science 250, 546-549 (1990)		
RLi		Jones, P.M. et al., Endocr Rev 19, 429-461 (1998)	manister 2	المنتبار بالمنافقة والمنافقة المنافقة المنافقة المنافقة

Examiner	0 '4' 0	Date 7/0/ C	
Signature	Kushing In	Considered 7/8/2006	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

and the specific property.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

LI, RUIXIANG

0402-UTL-5

Under the Paperwork Reduction Act of 1995, no persons an		t and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.	
Substitute for form 1449/PTO		Complete if Known	and the second of the second second
1993/10/10/10/10/10/10/10/10/10/10/10/10/10/	Application Number	10/518,128	1
NFORMATION DISCLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Bronislava Gedulin	1
(Use as many sheets as necessary)	Art Unit	1646	
(Ose as many sheets as necessary)			4

Attorney Docket Number

Examiner Name

Sheet

16

31

Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²	
initiais	140.	number(s), publisher, city and/or country where published.		
RLI \		Kanatani, A., et al., Biochem Biophys Res Commun 272, 169-173 (2000)		
		Kanatani, A., et al., Biochem Biophys Res Commun 266, 88-91 (1999)		
		Kanatani, A., et al., Endocrinology 141, 1011-1016 (2000)		
		Karlsson S, et al., Acta Physiol Scand.157:305-306 (1996)		क ा - होता है तमने हेर प्रदेश है है है
		Kato, K., et al., Peptides 16, 1257-1262 (1995)		
		Kawakubo, K., et al., Brain Res 854, 30-34 (2000)		
		Keire, D.A., et al., Peptides 23, 305-321 (2002)		
		Keire, D.A., et al., Biochemistry 39, 9935-9942 (2000)		
		Keire, D.A., et al., Am J Physiol 279, G126-G131 (2000)		
RLi		Kimmel, J.R., et al., Endocrinology 83, 1323-1330 (1968)		

Examiner Signature	Centing La	Date Considered	7/8/2008
ACT 144 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (07-05)

and the Committee of the Contraction .

0402-UTL-5

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/518,128 INFORMATION DISCLOSURE Filing Date June 13, 2003 STATEMENT BY APPLICANT **First Named Inventor** Bronislava Gedulin Art Unit 1646 (Use as many sheets as necessary) **Examiner Name** LI, RUIXIANG

Attorney Docket Number

Sheet

17

31

of

Cuamias:	Cito	NON PATENT LITERATURE DOCUMENTS	_	_
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T²
RL;		Kirby, D.A., et al., J Med Chem 36, 3802-3808 (1993)		
}		Kirby, D.A., et al., J Med Chem 38, 4579-4586 (1995)	\setminus	
		Kopelman, P.G. Nature 404, 635-643 (2000)		
		Korsgren, O., et al., Transplantation 45, 509-514 (1988)	1	
		Krasinski, S.D., et al., Mol Endocrinol 5, 433-440 (1991)		eri, ès
		Krstenansky, J.L., et al., Proc Natl Acad Sci U S A 86, 4377-4381 (1989)		
		Krstenansky, J.L., et al., Neuropeptides 17, 117-120 (1990)		
		Kruger, D.F., et al., Diabetes Educ 25, 389-397; quiz 398 (1999)		
		Kumagai Braesch, M., et al., Transplant Proc 24, 679-680 (1992)	Π	-
RL;		Kushi, A., et al., Proc Natl Acad Sci U S A 95, 15659-15664 (1998)		

Examiner	0	Date	٦
Signature	Kushing In	Considered 7/6/2006	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO.—Time will vary depending upon the individual case.—Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Substitu	Substitute for form 1449/PTO				\	
0003410	.01011011111111111111111111111111111111			Application Number	10/518,128	7
INFO	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003	•
STA	STATEMENT BY APPLICANT			First Named Inventor	Bronislava Gedulin	
	(Use as many she		***************************************	Art Unit	1646	7
	(Ose as many sne	ers 93 ti	oce ssary)	Examiner Name	LI, RUIXIANG	7 ·
Sheet	18	of	31	Attorney Docket Number	0402-UTL-5	Jane to consider anticipal visited

		NON PATENT LITERATURE DOCUMENTS		
Examiner nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RL;		Lacy, P.E., et al., Science 254, 1782-1784 (1991)		
		Landegren, U., et al., Science 241, 1077-1080 (1988)		
		Leban, J.J., et al., J Med Chem 38, 1150-1157 (1995)		
		Leibowitz, S.F. et al., Peptides 12, 1251-1260 (1991)		
		Liu, C.D., et al., J Gastrointest Surg 5, 147-152 (2001)		
		Liu, X.M., et al., Diabetes 40, 858-66 (1991)	· PANKER D	Same Modern Hely (1881 Masser
		Lloyd, K.C.K., et al., Am J Physiol 270, G123-G127 (1996)		
		Lluis, F., et al., Gastroenterology 94, 137-144 (1988)		
		Lundberg, J.M., et al., Proc Natl Acad Sci U S A 79, 4471-4475 (1982)		
RL;		Lundell, I., et al., J Biol Chem 270, 29123-29128 (1995)		

Examiner Signature	Rusking I-	Date Considered	7/4/206
Oignature	· <i>U</i> •—	Considered	, , , , , , , , , , , , , , , , , , ,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	ite for form 1449/PTO		ct of 1995, no persons at	Complete if Known		
	10 10 10 10 11 17 10 10			Application Number	10/518,128	
INF	ORMATION	V DIS	CLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Bronislava Gedulin			
	(Use as many sheets as necéssary)			Art Unit	1646	
	(Ose as many sn		iecessary)	Examiner Name	LI, RUIXIANG	
Sheet	19	of	31	Attorney Docket Number	0402-UTL-5	

· · · · · ·	·		PRINCE SECTION	<u>ታይ</u> . ምሳሌሎላያኒስኝ
Examiner Initials* Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Lyznicki JM, et al., Am Fam Physician. 63:2185-2196 (2001)		
		Makimura, H. et al., Obesity Poster Abstract No. 118 "Adrenalectomy stimulated hypothalamic proopiomelanocortin mRNA but does not correct obesity in diet-induced obese mice."		
		Malaisse-Lagae, F., et al., Experientia 33, 915-917 (1977)		
		Markison S., et al., Obesity Poster Abstract No. 119 "Selective melanin-concentrating hormone receptor antagonists decrease feeding in rodents."		
		Marsh, D.J., et al., Nat Med 4, 718-721 (1998)		
		Martin, J.R. Brain Res 1002, 11-20 (2004)		•
		Martin, N.M., et al., Int J Obes Relat Metab Disord 28, 886-893 (2004)		
		Mashiko, S., et al., Endocrinology 144, 1793-1801 (2003)		governmenter nga
		Mashiko et al., Obesity Poster Abstract No. 120 "Characterization of neuropeptide Y Y5 receptor mediated obesity in mice."		
RLi		Maxam, A.M. et al., Proc Natl Acad Sci U S A 74, 560-564 (1977)		

Examiner	9	Date	-/4/	
Signature	Kushang L-	Considered) [] [] [] [] [] [] [] [] [] [

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a velid OMB contains.

Substitu	Substitute for form 1449/PTO			Complete if Known		
	10 10 10 10 10 10 10 10 10 10 10 10 10 1			Application Number	10/518,128	
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003	
STA	STATEMENT BY APPLICANT		First Named Inventor	Bronislava Gedulin		
Ī	(Use as many sheets as necessary)			Art Unit	1646	
	1030 as many sinc	7013 03 7	iocessary)	Examiner Name	LI, RUIXIANG	
Sheet	20	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cit No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RLi		Mazelin L, et al., J Auton Nerv Syst.73:38-45 (1998)	st report by a	i provinci adoliko osi žiplinjenjim v
		Medeiros, M.D. et al., Endocrinology 134, 2088-2094 (1994)		
		Michel, M.C., et al., Pharmacol Rev 50, 143-150 (1998)		
1.		Morley, J.E. Neuropsychobiology 21, 22-30 (1989)		,
		Morley, J.E. et al., Life Sci 41, 2157-2165 (1987)		
		Morley, J.E., et al., Am J Physiol 267, R178-R184 (1994)		
		Morley, J.E., et al., Brain Res 341, 200-203 (1985)		
		Morris GP, et al., Gastroenterology 96:795-803 (1989)		
		Mulder, H., et al., Microscopy-Research and Technique 43, 313-324 (1998)	14mm 1757.	Bers John Carlothin (Billian grossoft) (s. c.)
RL;		Mullins, D., et al., Mol Pharmacol 60, 534-540 (2001)		

Examiner	1 , ,	Date	-1:1- 1
Signature	Kushang In	Considered	7/8/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents. P.O. Box 1450. Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO		ct or 1993, no persons ar		Complete if Known	
Subsulu	19 101 101111 1443/210			Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
				Art Unit	1646	
	(Use as many st	ieets as r	lecessary)	Examiner Name	LI, RUIXIANG	
Sheet	21	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
RLi		Munson, P.J. et al., Anal Biochem 107, 220-239 (1980)		
		Murakami, Y., et al., J Med Chem 42, 2621-2632 (1999)	w with the second	escotto car Ato 1986
		Murase, S., et al., J Biochem (Tokyo) 119, 37-41 (1996)		
		Myers, R.M., et al., Science 230, 1242-1246 (1985)		,
		Myers, R.M., et al., Nature 313, 495-498 (1985)		
		Naeve, C.W., et al., Biotechniques 19, 448-453 (1995)		
		Nakajima, M., et al., J Pharmacol Exp Ther 268, 1010-1014 (1994)		:
		Nakazawa, H., et al., Proc Natl Acad Sci U S A 91, 360-364 (1994)		
		Naslund, E., et al., Int J Obes Relat Metab Disord 23, 304-311 (1999)		
RLi		Ngo, J.T., et al., The protein folding problem and tertiary structure prediction, pp. 491-495. Boston: Birkhauser (1994)	in property and the	ago con ente lito talif

Examiner	0	Date	7/8/2.1
Signature	Kushang Tur	Considered	1/8/236

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ing of the control of the spring of the con-

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI

Substitu	rte for form 1449/PTO			and the second s	Complete if Known		
300300	no lor lorin 144ar 10			Application Number	10/518,128		
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin		
	///aa aa aba			Art Unit	1646		
(Use as many sheets as necessary)				Examiner Name	LI, RUIXIANG		
Sheet	22	of	31	Attorney Docket Number	0402-UTL-5		

	0:4-	NON PATENT LITERATURE DOCUMENTS	_	_
xaminer nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1	Γ ²
RLi		Nieuwenhuizen, A.G., et al., Diabetologia 37, 871-878 (1994)		
		Nightingale, J.M., et al., Gut 39, 267-272 (1996)		
		Odagiri, H., et al., J Biol Chem 271, 1909-1915 (1996)		_
		Okada, S., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 520B (1993)		-571
		Okumura, T., et al., Neuroscience Letters 178, 167-170 (1994)		
		Orita, M., et al., Proc Natl Acad Sci U S A 86, 2766-2770 (1989)		
		Otonkoski, T., et al., Diabetes 37, 286-291 (1988)		=
		Pappas, T.N., et al., Gastroenterology 91, 1386-1389 (1986)		1
		Pappas, T.N., et al., Am J Physiol 248, G118-G123 (1985)		=
RLi		Parker, E.M., et al., Eur J Pharmacol 349, 97-105 (1998)		=

Examiner Signature	Rushing L	Date Considered 7/8/2006	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

on the east of the following a

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			ct of 1995, no persons as	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitu	te for form 1449/	PIO		Application Number	10/518,128
INF	ORMATI	ON DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	// t	h-		Art Unit	1646
	(Use as mar	ny sheets as n	recessary)	Examiner Name	LI, RUIXIANG
Sheet	23	of	31	Attorney Docket Number	0402-UTL-5

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T	ĺ
nitials*	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-in number(s), publisher, city and/or country where published.		T ²	
RLI		Parker, E.M., et al., Peptides 21, 393-399 (2000)		
		Parker, S.L. et al., Can J Physiol Pharmacol 78, 150-161 (2000)		
		Pelleymounter, M.A., et al., Science 269, 540-543 (1995)		
		Pheng, L.H., et al., Br J Pharmacol 139, 695-704 (2003)		
		Pironi, L., et al., Gastroenterology 105, 733-739 (1993)	e expansions	opper the law electric transfer in the state of the state
		Pi-Sunyer, F.X. Obes Surg 12 Suppl 1, 6S-11S (2002)		
		Pokrovsky, V.I. Nephrotomy: renal insufficiency. In: Academician of RAMS, (Ed.) Small Medical Encyclopedia, pp. 59-62. Moscow: Meditisina Publishers] (1996) - English tra		
		Potter, E.K., et al., Eur J Pharmacol 267, 253-262 (1994)		
1		Randle, P.J. Diabetes Metab Rev 14, 263-283 (1998)		
RLi	1	Renshaw, D. et al., Curr Drug Targets 6, 171-179 (2005)		

Examiner Signature	Runding La	Date Considered	7/8/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and the complete of the complete of the complete of the complete of the chief information officer, U.S. Patent and the complete of the complete of the complete of the chief information officer, U.S. Patent and the complete of the complete of the chief information officer, U.S. Patent and the complete of the complete of the chief information of the chief i Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTC		CC OF 1995, NO PERSONS AS	a required to respond to a contector	n of information unless it contains a valid OMB control number. Complete if Known
Journal	Ne los lossis 1443/F16	•		Application Number	10/518,128
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	// lan an	.		Art Unit	1646
	(Use as many s	neets as i	iecessary)	Examiner Name	LI, RUIXIANG
Sheet	24	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	·
RLi		Rhodes, C.J. et al., J Cell Biol 105, 145-153 (1987)		
		Rico, L. et al., Obesity Poster Abstract No. 117 "Early and dissociated leptin and insulin resistance in transgenic mice overexpressing leptin from keratinocytes."		
		Rissanen, A., et al., BMJ 301, 835-837 (1990)		. •
		Rist, B., et al., Eur J Biochem 247, 1019-1028 (1997)		
		Rist, B., et al., FEBS Lett 394, 169-173 (1996)		``
		Robbins, L.S., et al., Pathologic Basis of Disease, 3rd edn. pp. 972-990. Philadelphi: W. B. Saunders Company] (1984)		
		Saiki, R.K., et al., Nature 324, 163-166 (1986)		kan tuu est ans unersmin
7		Saiki, R.K., et al., Proc Natl Acad Sci U S A 86, 6230-6234 (1989)		
1		Sainsbury, A., et al., Genes Dev 16, 1077-1088 (2002)		
RLi		Saleeba, J.A. et al., Methods Enzymol 217, 286-295 (1993)		

Examiner	0 ' '	Date	-101-
Signature	Kusciang Li	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
p a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449/PT	0		Complete if Known			
Judania	10 10 10 11 17 27 1	•		Application Number	10/518,128		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Bronislava Gedulin		
	(Use as many	-ht		Art Unit	1646		
	(Use as many :	sneets as n		Examiner Name	LI, RUIXIANG		
Sheet	25	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	gas om hann the adiations
RLi		Sandberg M, et al., J Med Chem.41:2481-2491 (1998)		
		Sander, M., et al., Proc Natl Acad Sci U S A 95, 11572-11577 (1998)		
		Sanger, F., et al., Proc Natl Acad Sci U S A 74, 5463-5467 (1977)		
		Sato, N., et al., J Med Chem 46, 666-669 (2003)		:
		Savage, A.P., et al., Gut 28, 166-170 (1987)		;
		Scatchard, G., Ann NY Acad Sci 51, 660 (1949)		
		Scheen, A.J. Drugs 54, 355-368 (1997)		
,		Schmidt PT, et al., Eur J Gastroenterol Hepatol 17:207-212 (2005)	Section 1985	nav Jim Inav - En Indelffat yn
		Schuit, F.C. Horm Res 46, 99-106 (1996)		
RL;		Schwartz, M.W., et al., Nature 404, 661-671 (2000)		

Examiner	0 ' i -	Date	- 1.1
Signature	Kurxiang U	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitu	te for form 1449/PTO		-	Complete if Known			
Guosaio				Application Number	10/518,128		
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin		
	(Use as many she		oooccand	Art Unit	1646		
	(USB as many site	70 to do 11	ecessary)	Examiner Name	LI, RUIXIANG		
Sheet	26	of	31	Attorney Docket Number	0402-UTL-5		

	Lau	NON PATENT LITERATURE DOCUMENTS		4
Examiner nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	a populár especial especial
RLi		Servin, A.L., et al., Endocrinology 124, 692-700 (1989)		
		Shan, L., et al., Science 297, 2275-2279 (2002)		
		Sheikh, S.P. Am J Physiol 261, G701-G715 (1991)		
		Silva, A.P., et al., Clin Chim Acta 326, 3-25 (2002)		
		Simeonovic, C.J. et al., Aust J Exp Biol Med Sci 60 Pt 4, 383-390 (1982)		
		Slack, J.M. Development 121, 1569-1580 (1995)		
		Small, C.J., et al., Proc Natl Acad Sci U S A 94, 11686-11691 (1997)		
		Soll, R.M., et al., Eur J Biochem 268, 2828-2837 (2001)	topate ogs. A	des in control de Meso.
\downarrow		Souers AJ, et al., Tetrahedron 57:7431-7448 (2001)		
RLi		Stanley, B.G., et al., Peptides 6, 1205-1211 (1985)		1

Examiner		,	Date	-1.1
Signature	Kushang	i du:	Considered	7/8/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

大型 热力键 化烷化

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/518,128 **Filing Date** INFORMATION DISCLOSURE June 13, 2003 STATEMENT BY APPLICANT First Named Inventor Bronislava Gedulin Art Unit 1646 (Use as many sheets as necessary) **Examiner Name** LI, RUIXIANG **Attorney Docket Number** Sheet 0402-UTL-5 27 131

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		
Initials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RLi		St-Onge, M.P. et al., J Nutr 132, 329-332 (2002)		
		Sullivan, S.J., et al., Science 252, 718-721 (1991)		
		Surwit, R.S., et al., Metabolism - Clinical and Experimental 44, 645-651 (1995)		
		Suzuki, T., et al., Gastroenterology 85, 114-121 (1983)	Company (CES) (C)	gest om det en ett ette først
		Taniguchi, H., et al., Eur J Pharmacol 312, 227-233 (1996)		
		Tatemoto, K. Proc Natl Acad Sci U S A 79, 2514-2518 (1982)		
		Tatemoto, K. Proc Natl Acad Sci U S A 79, 5485-5489 (1982)		
		Tatemoto, K., et al., Nature 296, 659-660 (1982)		
		Tatemoto, K., et al., Proc Natl Acad Sci U S A 89, 1174-1178 (1992)		
RL;		Tatemoto, K., et al., Biochem Biophys Res Commun 157, 713-717 (1988)		

Examiner Signature	Ruixing L	Date Considered	7/8/2-6

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI ander the Pagenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	ite for form 1449/PTO				Complete if Known			
Subsuit	NE IOT IOTH 1445/PTO			Application Number	10/518,128			
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003			
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin			
				Art Unit	1646			
	(Use as many s	neets as n	lecessary)	Examiner Name	LI, RUIXIANG			
Sheet	28	of	31	Attorney Docket Number	0402-UTL-5			

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
RLi	:	Taylor, I.L. J Dairy Sci 76, 2094-2101(1993)		
		Taylor, I.L. et al., Am J Physiol 248, G277-G280 (1985)		
		Teyssen, S., et al., Pancreas 13, 80-88 (1996)		
		Thorens, B., et al., Proceedings of the National Academy of Sciences of the United States of America 87, 6492-6496 (1990)		
		Thum, A., et al., Exp Clin Endocrinol Diabetes 110, 113-118 (2002)		
		Tito JM, et al., Am J Surg.165:690-696 (1993)	20 (2)253	Bas, makanish nitima
		Totheroh, G., "Science Offers Promising Treatment for an Overweight Nation" CBN News (Sept 4, 2003)		
		Tsai JH, et al., Bioorg Med Chem 7:29-38 (1999)		
		Tschop, M., et al., Nature 430, 1 p following 165; discussion 2 p following 165 (2004)		
RLi		Tseng, W.W. et al., Peptides 23, 389-395 (2002)		

Examiner Signature Ruixing Li Considered 7/3/2006				
Signature I Considered I /101 o	Examiner			,
	Signature	Kushang Li	Considered // France	,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				e required to respond to a collection	od Information unless it contains a valid OMB control number. Complete if Known
Substitu	10 10 10 11 143F10			Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	vote on e		Art Unit	1646
	(Use as many sine	70 to 45 f	iecessary)	Examiner Name	LI, RUIXIANG
Sheet	29	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т	-2
RLi		Tuch, B.E., et al., J Endocrinol 132, 159-167 (1992)		
		Turnbull, A.V., et al., Diabetes 51, 2441-2449 (2002)		-
		Ueno, N., et al., Gastroenterology 117, 1427-1432 (1999)		_
	Upchurch, B.H., et al., Development 120, 245-252 (1994)			=
		Valera, A., et al., J Biol Chem 269, 28543-28546 (1994)		
		Valet, P., et al., J Clin Invest 85, 291-295 (1990)		=
		van Santbrink, E.J. et al., J Clin Endocrinol Metab 82, 3597-602 (1997)		=
		Verchere, C.B., et al, Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 517B., (1993)		_
		Virgilio AA, et al., Tetrahedron 53:6635-6644 (1997)		=
RLi		Voisin, T., et al., J Biol Chem 268, 20547-20554 (1993)		<u>_</u>

Examiner Signature	Russiang L.	Date Considered	7/16/2026

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
, Substitu	10 101 101111 1443/110	Application Number 10/518,128 TION DISCLOSURE Filing Date June 13, 2003 First Named Inventor Bronislava Gedulin Art Unit 1646				
INF	ORMATION					
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
	IFORMATION DISCLOSUR TATEMENT BY APPLICAN (Use as many sheets as necessary)	occesand	Art Unit	1646		
	(USB as many sn	AGES GS 1		Examiner Name	LI, RUIXIANG	
Sheet	30	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ²	2
RLI		Wager-Page, S.A., et al., Can J Physiol Pharmacol 71, 768-775 (1993)		
		Wahoff, D.C., et al., Transplant Proc 26, 804 (1994)		
		Walker, M.W., et al., J Neurosci 8, 2438-2446 (1988)		
		Walker, M.W., et al., Peptides 18, 609-612 (1997)		-
		Wang, Z.L., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 518B (1993)		
		Weinberg, D.H., et al., J Biol Chem 271, 16435-16438 (1996)		
		Wells, J.A. Biochemistry 29, 8509-8517 (1990)		=
·		Widdowson, P.S., et al., Brain Res 778, 242-250 (1997)		
V		Wilding, J.P. Diabet Med 19, 619-627 (2002)		-
RLi		Wiley, J.W., et al., Gastroenterology 100, 865-872 (1991)	1	<u> </u>

Examiner	0	^	Date	- lui
Signature	Kushang	<u>ኤ</u>	Considered	116/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons at Substitute for form 1449/PTO				l a composito de c	Complete if Known	
300300	118 101 101111 1443/F10			Application Number	10/518,128	
INF	ORMATION	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
				Art Unit	1646	
	(Use as many sh	eets as n	lecessary)	Examiner Name	LI, RUIXIANG	
Sheet	31	of	31	Attorney Docket Number	0402-UTL-5	

 -	·	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Wilson, J.D., et al., Diabetes 38 Suppl 1, 217-219 (1989)	
		Wimalawansa, S.J. Crit Rev Neurobiol 11, 167-239 (1997)	
		Yang, H., et al., Br J Pharmacol 123, 1549-1554 (1998)	
		Yang, H. et al., Am J Physiol 268, G943-G948 (1995)	
		Yoshinaga, K., et al. Am J Physiol 263, G695-G701 (1992)	
		Young, A.A. et al., Program and Abstracts, 10th International Congress of Endocrinology 419 (poster P2-58) (1996)	
		Young, A.A., et al., Metabolism 45, 1-3 (1996)	
		Zai, H., et al., Regul Pept 61, 181-188 (1996)	
		HYPERDICTIONARY – definition of "Structure Activity Relationship"	
RLi		On-Line Medical Dictionary. Dept. of Oncology, University of Newcastle upon tyne. The Cancerweb Project Copyright 1997-2004 (definitions of "hyperlipoproteinaemia"; "hyperlip	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onsidered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.